Kashiv and Intas Forge Peptide Pact to Expand Global Drug Access

PISCATAWAY, NJ – February 09, 2026

In a significant move poised to reshape the biopharmaceutical landscape in Europe and Asia, U.S.-based Kashiv BioSciences has entered into an exclusive licensing and supply agreement with Indian multinational Intas Pharmaceuticals. The deal centers on an undisclosed complex peptide product, leveraging the strengths of both companies to penetrate key markets including the pan-European region, the United Kingdom, and India.

Under the terms of the agreement, Kashiv BioSciences will spearhead the development, regulatory registration, manufacturing, and supply of the advanced therapeutic. Intas, along with its prominent European subsidiary Accord Healthcare, will take the helm for commercialization and distribution, utilizing its vast and established networks to bring the product to patients and healthcare providers.

This collaboration highlights a growing trend of strategic, cross-continental partnerships designed to navigate the complex and costly process of bringing specialized medicines to a global audience. By dividing responsibilities, the companies aim to streamline the path from factory to pharmacy, accelerating access to what is often a high-cost and technically challenging class of drugs.

A Strategic Alliance for Global Reach

The partnership is a masterclass in strategic synergy. Kashiv BioSciences, a vertically integrated biopharmaceutical firm known for its robust R&D and manufacturing capabilities, gains immediate and extensive access to lucrative international markets without the immense cost and time required to build a commercial infrastructure from the ground up.

“Our partnership with Intas, leveraging its strong pan-European presence through Accord, enables Kashiv to expand our commercial reach across key European, UK, and Indian markets and strengthen our overall portfolio in the regions,” said Dr. Sandeep Athalye, Global CEO of Kashiv BioSciences. “This collaboration reflects our shared commitment to improving patient outcomes and aligns with our mission to make high-quality, affordable therapies more accessible for patients worldwide.”

For Intas and Accord Healthcare, the deal enriches their portfolio with a sophisticated, high-value product. Accord Healthcare is one of the fastest-growing pharmaceutical companies in Europe, with a footprint in over 85 countries, providing a powerful engine for commercial rollout. This allows the Indian-headquartered giant to reinforce its market position with cutting-edge therapies developed by a specialized partner.

“We are pleased to partner with Kashiv BioSciences to expand access to high-quality therapies across Europe, the UK and India,” stated Mr. Binish Chudgar, Chairman and Managing Director of Intas Pharmaceuticals. “By combining our capabilities, we aim to strengthen our presence and better serve the unmet needs of patients and healthcare professionals.”

The Rising Tide of Complex Peptides

At the heart of this agreement is a 'complex peptide product,' a class of therapeutics that represents one of the fastest-growing segments of the pharmaceutical industry. Peptides, which are short chains of amino acids, act as highly specific signaling molecules in the body, bridging the gap between traditional small-molecule drugs and large-molecule biologics like monoclonal antibodies.

These therapies are critical in treating a wide array of conditions, including metabolic disorders like diabetes and obesity, various forms of cancer, osteoporosis, and infectious diseases. The global peptide therapeutics market, valued at over $45 billion in 2022, is projected to exceed $80 billion by 2030, driven by the rising prevalence of chronic diseases and the high efficacy of these treatments.

However, the development and manufacturing of complex peptides are fraught with challenges. Their synthesis is intricate, they can be unstable, and their administration often requires injections. These technical hurdles create a high barrier to entry, making strategic partnerships essential for companies looking to compete in the space. This agreement exemplifies how specialized R&D firms like Kashiv and commercial powerhouses like Intas can join forces to overcome these challenges and capitalize on the immense market opportunity.

Navigating the Regulatory Gauntlet

A crucial component of the deal, and a testament to Kashiv’s expertise, is its responsibility for securing regulatory approval across three distinct and rigorous systems: the European Medicines Agency (EMA), the UK's Medicines and Healthcare products Regulatory Agency (MHRA), and India's Central Drugs Standard Control Organization (CDSCO).

Bringing a complex peptide product to market, particularly as a generic or biosimilar, is not a simple task. Regulators require extensive data demonstrating that the product is comparable in quality, safety, and efficacy to the original innovator drug. For peptides, this involves proving similarity in structure, purity, and biological activity, as well as assessing the potential for an immune response in patients.

The EMA has a well-defined pathway for biosimilars, while the MHRA has established its own parallel system post-Brexit. In India, the CDSCO has robust guidelines to ensure the quality of both biosimilars and generic drugs. Kashiv’s role in navigating these complex, multi-layered regulatory landscapes is a critical value-add that underpins the entire partnership, de-risking the process for its commercial partner.

The Patient Impact: Bridging the Access Gap

Beyond the corporate strategy and market dynamics, the collaboration promises a tangible impact on patients and healthcare systems. The introduction of a new, high-quality complex peptide product is expected to increase competition, which historically leads to more affordable pricing. For national health systems like the UK's NHS and other European payers constantly grappling with rising drug costs, the availability of more cost-effective alternatives can unlock significant savings and allow for the treatment of more patients.

In India, a rapidly growing market with a vast patient population, the need for affordable access to advanced medicines is particularly acute. This partnership directly addresses that need by combining U.S.-developed technology with India's manufacturing and distribution prowess, aligning perfectly with the stated missions of both organizations.

Ultimately, this alliance is more than a business transaction; it represents a modern blueprint for global pharmaceutical collaboration. By strategically combining specialized innovation with commercial scale, Kashiv and Intas are not only positioning themselves for market success but are also building a more efficient pathway to deliver the next generation of essential medicines to a worldwide patient population.